Algernon Pharmaceuticals Inc. Logo

Algernon Pharmaceuticals Inc.

AGNPF

(1.8)
Stock Price

0,04 USD

-364.37% ROA

-131.4% ROE

-0.66x PER

Market Cap.

1.738.007,01 USD

0% DER

0% Yield

0% NPM

Algernon Pharmaceuticals Inc. Stock Analysis

Algernon Pharmaceuticals Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Algernon Pharmaceuticals Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.2x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

4 Net Profit Growth

This company's net profit has been consistently on the rise over the past three years, indicating a strong financial performance and making it an appealing investment opportunity.

5 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

6 ROE

The stock's ROE indicates a negative return (-149.05%) on shareholders' equity, suggesting poor financial performance.

7 ROA

The stock's ROA (-769.12%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Algernon Pharmaceuticals Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Algernon Pharmaceuticals Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Algernon Pharmaceuticals Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Algernon Pharmaceuticals Inc. Revenue
Year Revenue Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Algernon Pharmaceuticals Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2015 181.383
2016 195.492 7.22%
2017 354.474 44.85%
2018 93.816 -277.84%
2019 605.734 84.51%
2020 2.675.493 77.36%
2021 4.797.012 44.23%
2022 2.293.448 -109.16%
2023 1.095.159 -109.42%
2024 416.036 -163.24%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Algernon Pharmaceuticals Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 549.086
2016 2.302.400 76.15%
2017 1.034.919 -122.47%
2018 854.739 -21.08%
2019 1.074.138 20.43%
2020 4.719.637 77.24%
2021 2.459.788 -91.87%
2022 2.996.709 17.92%
2023 2.886.128 -3.83%
2024 1.304.684 -121.21%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Algernon Pharmaceuticals Inc. EBITDA
Year EBITDA Growth
2015 579
2016 -2.886.538 100.02%
2017 -878.545 -228.56%
2018 -907.605 3.2%
2019 -1.898.529 52.19%
2020 -8.748.828 78.3%
2021 -8.051.124 -8.67%
2022 -5.948.540 -35.35%
2023 -3.650.287 -62.96%
2024 -1.838.320 -98.57%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Algernon Pharmaceuticals Inc. Gross Profit
Year Gross Profit Growth
2015 0
2016 -47.961 100%
2017 -127.538 62.39%
2018 -40.950 -211.45%
2019 -26.995 -51.69%
2020 0 0%
2021 0 0%
2022 -34.936 100%
2023 -50.398 30.68%
2024 -24.340 -107.06%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Algernon Pharmaceuticals Inc. Net Profit
Year Net Profit Growth
2015 -729.890
2016 -6.876.788 89.39%
2017 -1.890.605 -263.73%
2018 -937.594 -101.64%
2019 -1.895.563 50.54%
2020 -8.538.207 77.8%
2021 -7.734.080 -10.4%
2022 -6.054.356 -27.74%
2023 -6.781.200 10.72%
2024 5.775.632 217.41%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Algernon Pharmaceuticals Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 -3
2016 -8 62.5%
2017 -2 -700%
2018 -1 0%
2019 -1 0%
2020 -2 100%
2021 -1 -100%
2022 -1 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Algernon Pharmaceuticals Inc. Free Cashflow
Year Free Cashflow Growth
2015 -337.265
2016 -1.535.982 78.04%
2017 -1.307.611 -17.46%
2018 -616.507 -112.1%
2019 -1.847.974 66.64%
2020 -6.709.674 72.46%
2021 -7.947.065 15.57%
2022 -3.057.349 -159.93%
2023 -2.612.508 -17.03%
2024 -1.815.419 -43.91%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Algernon Pharmaceuticals Inc. Operating Cashflow
Year Operating Cashflow Growth
2015 -337.265
2016 -1.407.694 76.04%
2017 -1.220.987 -15.29%
2018 -616.507 -98.05%
2019 -1.782.228 65.41%
2020 -6.609.933 73.04%
2021 -7.822.617 15.5%
2022 -2.912.741 -168.57%
2023 -2.553.008 -14.09%
2024 -1.785.802 -42.96%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Algernon Pharmaceuticals Inc. Capital Expenditure
Year Capital Expenditure Growth
2015 0
2016 128.288 100%
2017 86.624 -48.1%
2018 0 0%
2019 65.746 100%
2020 99.741 34.08%
2021 124.448 19.85%
2022 144.608 13.94%
2023 59.500 -143.04%
2024 29.617 -100.9%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Algernon Pharmaceuticals Inc. Equity
Year Equity Growth
2015 1.227.840
2016 2.122.745 42.16%
2017 1.588.808 -33.61%
2018 1.365.865 -16.32%
2019 4.972.639 72.53%
2020 12.216.915 59.3%
2021 9.115.318 -34.03%
2022 5.624.658 -62.06%
2023 1.473.939 -281.61%
2024 1.962.124 24.88%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Algernon Pharmaceuticals Inc. Assets
Year Assets Growth
2015 1.401.206
2016 2.273.123 38.36%
2017 1.636.558 -38.9%
2018 1.422.899 -15.02%
2019 5.338.103 73.34%
2020 12.823.968 58.37%
2021 10.137.632 -26.5%
2022 8.140.757 -24.53%
2023 4.193.699 -94.12%
2024 3.893.168 -7.72%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Algernon Pharmaceuticals Inc. Liabilities
Year Liabilities Growth
2015 173.366
2016 150.378 -15.29%
2017 47.750 -214.93%
2018 57.034 16.28%
2019 365.464 84.39%
2020 607.053 39.8%
2021 1.022.314 40.62%
2022 2.516.099 59.37%
2023 2.719.760 7.49%
2024 1.931.044 -40.84%

Algernon Pharmaceuticals Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.12
Price to Earning Ratio
-0.66x
Price To Sales Ratio
0x
POCF Ratio
-0.65
PFCF Ratio
-0.64
Price to Book Ratio
0.88
EV to Sales
0
EV Over EBITDA
-0.38
EV to Operating CashFlow
-0.43
EV to FreeCashFlow
-0.42
Earnings Yield
-1.51
FreeCashFlow Yield
-1.56
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.49
Graham NetNet
-0.06

Income Statement Metrics

Net Income per Share
-0.12
Income Quality
1.02
ROE
-2.14
Return On Assets
-0.41
Return On Capital Employed
-1.01
Net Income per EBT
1
EBT Per Ebit
0.81
Ebit per Revenue
0
Effective Tax Rate
0.04

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.12
Free CashFlow per Share
-0.12
Capex to Operating CashFlow
-0.02
Capex to Revenue
0
Capex to Depreciation
1.69
Return on Invested Capital
-1.48
Return on Tangible Assets
-3.64
Days Sales Outstanding
0
Days Payables Outstanding
18608.38
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.02
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,03
Book Value per Share
0,09
Tangible Book Value per Share
-0.06
Shareholders Equity per Share
0.09
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.21
Current Ratio
0.36
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
1933374
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.82
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Algernon Pharmaceuticals Inc. Dividends
Year Dividends Growth

Algernon Pharmaceuticals Inc. Profile

About Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

CEO
Mr. Christopher J. Moreau
Employee
0
Address
700 West Pender Street
Vancouver, V6C 1G8

Algernon Pharmaceuticals Inc. Executives & BODs

Algernon Pharmaceuticals Inc. Executives & BODs
# Name Age
1 Mr. James F. Kinley C.A., CPA
Chief Financial Officer
70
2 Dr. Christopher Bryan Ph.D.
Vice President of Research & Operations
70
3 Mr. Christopher J. Moreau
Chief Executive Officer & Director
70

Algernon Pharmaceuticals Inc. Competitors